查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1536063

复合药局市场 - 分产品（口服、肠胃外、局部、眼科、鼻腔、直肠、耳科）治疗领域（疼痛管理、荷尔蒙替代）、应用、复合类型、无菌、配销通路、全球预测 2024 - 2032

Compounding Pharmacies Market - By Product (Oral, Parenteral, Topical, Ophthalmic, Nasal, Rectal, Otic) Therapeutic Area (Pain Management, Hormone Replacement), Application, Compounding Type, Sterility, Distribution Channel, Global Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 252 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在製药创新和研究的推动下，2024 年至 2032 年间，全球复合药房市场复合年增长率将超过 5.6%。持续的研发努力发现了新颖的复合技术和定製药物，为具有独特需求的患者提供了更多的治疗选择。根据美国 FDA 2023 年 1 月的报告，2022 年超过 60% 的新药申请涉及创新配方，凸显了正在进行的药物研究在推进复合技术和扩大个人化药物机会方面的重要作用。

这些进步使药剂师能够创造出更有效、个人化的配方，以满足特定的医疗状况、过敏和剂量要求。随着新技术和方法的出现，复方药局提供了创新的解决方案。前沿研究的整合增强了医疗保健提供者和患者之间的信任，增强了对定製药物的需求。

整个复方製药业根据产品、治疗领域、应用、复方类型、无菌、配销通路和地区进行分类。

由于需要为婴儿和儿童提供精确、客製化的药物，到 2032 年，父母细分市场将出现相当大的复合年增长率。标准剂量和配方通常不适合该群体，需要客製化解决方案。复方药房可以创造特定的剂型，例如液体或透皮凝胶，更容易让儿童摄入和吸收。此外，它们可以排除过敏原或不耐受物质，确保安全性和有效性。这种个人化满足了儿科患者独特的医疗需求，导致家长对复方药局的依赖日益增长。

到 2032 年，由于需要标准药物无法提供的个人化荷尔蒙疗法，荷尔蒙替代细分市场将占据显着的复合药房市场份额。患者通常需要根据其独特的生理需求量身定制特定的荷尔蒙组合和剂量，而复方药房可以提供这些组合和剂量。此外，他们可以配製生物相同的激素，密切模仿人体的天然激素，改善治疗效果并减少副作用。这种客製化提高了患者满意度和治疗效果，使复方药房成为有效荷尔蒙替代疗法的重要资源。

由于对个人化医疗的日益关注以及满足大规模生产药物无法满足的患者需求的需要，欧洲复合药房市场将从 2024 年到 2032 年以惊人的复合年增长率蓬勃发展。慢性疾病和复杂医疗状况的激增需要定製药物。对复合实践的监管支持，加上医疗保健提供者对客製化治疗的好处的认识不断提高，刺激了需求。该地区人口老化以及他们对个人化和有效治疗解决方案的需求将促进欧洲市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 全球老年人口不断增加，预期寿命提高
      • 已开发地区越来越多采用客製化医疗
      • 全球药品短缺
      • 复方药物的好处
    • 产业陷阱与挑战
      • 已开发经济体缺乏熟练的实验室技术人员和药剂师
      • 设备成本高、无菌环境维护成本高
      • 不稳定的监管环境
  • 成长潜力分析
  • 监管环境
    • 我们
    • 欧洲
    • 澳洲
  • 报销版图
    • 我们
    • 欧洲
    • 澳洲
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

  • 主要趋势
  • 口服
    • 固体製剂
      • 平板电脑
      • 胶囊
      • 颗粒剂
      • 粉末
      • 其他固体製剂
    • 液体製剂
      • 解决方案
      • 暂停
      • 乳液
      • 糖浆
      • 其他液体製剂
  • 专题
    • 药膏
    • 乳霜
    • 凝胶
    • 膏体
    • 其他局部产品
  • 直肠
    • 栓剂
    • 灌肠
    • 其他直肠产品
  • 注射用
    • 大容量注射剂 (LVP)
    • 小容量注射剂 (LVP)
  • 鼻腔
  • 眼科
  • 奥迪克

第 6 章：市场估计与预测：按治疗领域，2021 - 2032 年

  • 主要趋势
  • 疼痛管理
  • 荷尔蒙替代品
  • 皮肤科应用
  • 特殊药物
  • 营养补充品
  • 其他治疗领域

第 7 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 成人
  • 老年科
  • 兽医
  • 儿科

第 8 章：市场估计与预测：按复利类型，2021 - 2032

  • 主要趋势
  • 药物成分改变（PIA）
  • 目前无法使用的药品製造 (CUPM)
  • 药物剂量改变（PDA）
  • 其他复合类型

第 9 章：市场估计与预测：按无菌性分类，2021 - 2032 年

  • 主要趋势
  • 无菌剂型
  • 非无菌剂型

第 10 章：市场估计与预测：按配销通路划分，2021 - 2032 年

  • 主要趋势
  • 医院药房
  • 调配药房
  • 其他分销管道

第 11 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 波兰
    • 荷兰
    • 瑞典
    • 比利时
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 新加坡
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 卡达
    • 中东和非洲其他地区

第 12 章：公司简介

  • B. Braun Melsungen AG
  • Clinigen Group PLC
  • Dougherty's Pharmacy, Inc.
  • Fagron NV
  • Fresenius Kabi AG
  • ITC Compounding Pharmacy
  • Institutional Pharmacy Solutions, LLC
  • Lorraine's Pharmacy
  • McGuff Compounding Pharmacy Services
  • Nephron Pharmaceuticals Corporation
  • Pencol Compounding Pharmacy
  • Rx3 Compounding Pharmacy
  • Triangle Compounding Pharmacies
  • Valor Compounding Pharmacy, Inc.
  • Wedgewood Village Pharmacy, Inc.
简介目录
Product Code: 749

Global Compounding Pharmacies Market will experience over 5.6% CAGR between 2024 and 2032, ushered by pharmaceutical innovation and research. Continuous R&D efforts have lead to the discovery of novel compounding techniques and customized medications, enhancing treatment options for patients with unique needs. According to the U.S. FDA report in January 2023, over 60% of new drug applications in 2022 involved innovative formulations, highlighting the significant role of ongoing pharmaceutical research in advancing compounding techniques and expanding opportunities for personalized medications.

These advancements enable pharmacists to create more effective, personalized formulations that address specific medical conditions, allergies, and dosage requirements. As new technologies and methods emerge, compounding pharmacies provide innovative solutions. The integration of cutting-edge research fosters trust among healthcare providers and patients, bolstering the demand for tailored medications.

The overall compounding pharmacies industry is classified based on product, therapeutic area, application, compounding type, sterility, distribution channel, and region.

The parental segment will witness a considerable CAGR through 2032, owing to the need for precise, tailored medications for infants and children. Standard dosages and formulations often do not suit this group, necessitating customized solutions. Compounding pharmacies can create specific dosage forms, such as liquids or transdermal gels, which are easier for children to ingest and absorb. Additionally, they can exclude allergens or intolerant substances, ensuring safety and efficacy. This personalization meets the unique medical needs of pediatric patients, ushering in the growing reliance on compounding pharmacies in the parental segment.

The hormone replacement segment will garner a noteworthy compounding pharmacies market share by 2032, because of the need for personalized hormone therapies that standard medications cannot provide. Patients often require specific hormone combinations and dosages tailored to their unique physiological needs, which compounding pharmacies can create. Additionally, they can formulate bio identical hormones, closely mimicking the body's natural hormones, improving treatment outcomes and reducing side effects. This customization enhances patient satisfaction and treatment efficacy, making compounding pharmacies an essential resource for effective hormone replacement therapy.

Europe compounding pharmacies market will thrive at a remarkable CAGR from 2024 to 2032, due to an increasing focus on personalized medicine and the need to address patient requirements that mass-produced drugs cannot meet. The upsurge in chronic illnesses and complex medical conditions necessitates customized drugs. Regulatory support for compounding practices, coupled with a heightened awareness among healthcare providers about the benefits of tailored treatments, fuels the demand. The aging population in the region, along with their need individualized & effective therapeutic solutions will augment the market growth in Europe.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising geriatric population and improved life expectancy across the globe
      • 3.2.1.2 Rising adoption of customized medicine in the developed regions
      • 3.2.1.3 Shortage of drugs across the globe
      • 3.2.1.4 Benefits of compounded medication
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Lack of skilled lab technicians and pharmacists in developed economies
      • 3.2.2.2 High cost of equipment and maintenance of sterile environment
      • 3.2.2.3 Volatile regulatory scenario
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 U.S.
    • 3.4.2 Europe
    • 3.4.3 Australia
  • 3.5 Reimbursement landscape
    • 3.5.1 U.S.
    • 3.5.2 Europe
    • 3.5.3 Australia
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Oral
    • 5.2.1 Solid preparations
      • 5.2.1.1 Tablets
      • 5.2.1.2 Capsules
      • 5.2.1.3 Granules
      • 5.2.1.4 Powder
      • 5.2.1.5 Other solid preparations
    • 5.2.2 Liquid preparations
      • 5.2.2.1 Solutions
      • 5.2.2.2 Suspension
      • 5.2.2.3 Emulsion
      • 5.2.2.4 Syrup
      • 5.2.2.5 Other liquid preparations
  • 5.3 Topical
    • 5.3.1 Ointments
    • 5.3.2 Creams
    • 5.3.3 Gels
    • 5.3.4 Pastes
    • 5.3.5 Other topical products
  • 5.4 Rectal
    • 5.4.1 Suppositories
    • 5.4.2 Enema
    • 5.4.3 Other rectal products
  • 5.5 Parenteral
    • 5.5.1 Large volume parenterals (LVPs)
    • 5.5.2 Small volume parenterals (LVPs)
  • 5.6 Nasal
  • 5.7 Ophthalmic
  • 5.8 Otic

Chapter 6 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Pain management
  • 6.3 Hormone replacement
  • 6.4 Dermatology applications
  • 6.5 Specialty drugs
  • 6.6 Nutritional supplements
  • 6.7 Other therapeutic areas

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Adult
  • 7.3 Geriatric
  • 7.4 Veterinary
  • 7.5 Pediatric

Chapter 8 Market Estimates and Forecast, By Compounding Type, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Pharmaceutical ingredient alteration (PIA)
  • 8.3 Currently unavailable pharmaceutical manufacturing (CUPM)
  • 8.4 Pharmaceutical dosage alteration (PDA)
  • 8.5 Other compounding types

Chapter 9 Market Estimates and Forecast, By Sterility, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Sterile dosage form
  • 9.3 Non sterile dosage form

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 Hospital pharmacies
  • 10.3 Compounding pharmacies
  • 10.4 Other distribution channels

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 11.1 Key trends
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 France
    • 11.3.4 Spain
    • 11.3.5 Italy
    • 11.3.6 Poland
    • 11.3.7 Netherlands
    • 11.3.8 Sweden
    • 11.3.9 Belgium
    • 11.3.10 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 China
    • 11.4.2 Japan
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 South Korea
    • 11.4.6 Singapore
    • 11.4.7 Rest of Asia Pacific
  • 11.5 Latin America
    • 11.5.1 Brazil
    • 11.5.2 Mexico
    • 11.5.3 Argentina
    • 11.5.4 Rest of Latin America
  • 11.6 Middle East and Africa
    • 11.6.1 South Africa
    • 11.6.2 Saudi Arabia
    • 11.6.3 UAE
    • 11.6.4 Qatar
    • 11.6.5 Rest of Middle East and Africa

Chapter 12 Company Profiles

  • 12.1 B. Braun Melsungen AG
  • 12.2 Clinigen Group PLC
  • 12.3 Dougherty's Pharmacy, Inc.
  • 12.4 Fagron NV
  • 12.5 Fresenius Kabi AG
  • 12.6 ITC Compounding Pharmacy
  • 12.7 Institutional Pharmacy Solutions, LLC
  • 12.8 Lorraine's Pharmacy
  • 12.9 McGuff Compounding Pharmacy Services
  • 12.10 Nephron Pharmaceuticals Corporation
  • 12.11 Pencol Compounding Pharmacy
  • 12.12 Rx3 Compounding Pharmacy
  • 12.13 Triangle Compounding Pharmacies
  • 12.14 Valor Compounding Pharmacy, Inc.
  • 12.15 Wedgewood Village Pharmacy, Inc.